Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3D185 in Previously Treated Advanced or Metastatic Cholangiocarcinoma With FGFR2 Alterations
NCT05039892Phase 2Not yet recruiting
- Sponsor
- 3D Medicines Inc.
- Start
- Dec 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of segigratinib in cholangiocarcinoma (CCA), sponsored by 3D Medicines Inc.. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
segigratinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT05039892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05039892.